Tight­en­ing its wal­let for a clin­i­cal come­back, Seres lets go of CSO and 30% of work­force

Two weeks af­ter mov­ing to the helm of Seres Ther­a­peu­tics from the CFO of­fice, Er­ic Shaff has been charged with the un­en­vi­able task of lay­ing off his CSO along­side 30% of the biotech’s work­force in an ef­fort to nar­row the flow of cash to its mi­cro­bio­me clin­i­cal pro­grams.

Matthew Henn, pre­vi­ous­ly head of dis­cov­ery and mi­cro­bio­me R&D, will take David Cook’s place as Seres cuts 30 full-time and a num­ber of con­tract po­si­tions “pri­ma­ry re­lat­ed to re­search, man­u­fac­tur­ing and gen­er­al and ad­min­is­tra­tive ser­vices.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.